Bezuclastinib SUMMIT Data Reframe Cogent Biosciences Mastocytosis Opportunity [Yahoo! Finance]
Cogent Biosciences, Inc. (COGT)
Last cogent biosciences, inc. earnings: 11/8 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.cogint.com/investor-relations
Company Research
Source: Yahoo! Finance
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Cogent Biosciences reported new 48 week data from its SUMMIT trial of bezuclastinib in NonAdvanced Systemic Mastocytosis. The results showed durable and significant improvement in symptoms and key clinical endpoints for patients. The findings support the potential of bezuclastinib as a disease modifying therapy for this patient group. The updated data were presented at a leading medical meeting and had not been detailed in recent coverage. For Cogent Biosciences (NasdaqGS:COGT), the fresh SUMMIT data come as the stock trades at $38.89, with returns of 4.9% over the past week and 8.3% over the past month. The move over the past year is very large, and the stock is up 11.9% year to date. This puts extra attention on how the market interprets new clinical signals. Investors will likely focus on whether the durability of response and symptom relief seen at 48 weeks supp
Show less
Read more
Impact Snapshot
Event Time:
COGT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COGT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COGT alerts
High impacting Cogent Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
COGT
News
- Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswire
- Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026GlobeNewswire
- Cogent Biosciences (COGT) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Cogent Biosciences (COGT): Billionaire Stan Druckenmiller Admires Upside Potential of This Stock [Yahoo! Finance]Yahoo! Finance
- Cogent Biosciences: Blockbuster Potential, Premium Valuation, Still A 'Buy' [Seeking Alpha]Seeking Alpha
COGT
Sec Filings
- 4/23/26 - Form ARS
- 4/23/26 - Form DEF
- 4/23/26 - Form DEFA14A
- COGT's page on the SEC website